This module uses fundamental data of Arch Biopartners to approximate its Piotroski F score. Arch Biopartners F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Arch Biopartners. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Arch Biopartners financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arch Biopartners. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.
Arch
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Stock Based Compensation
Sale Purchase Of Stock
Net Borrowings
Change To Netincome
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Other Current Assets
Other Stockholder Equity
Total Liab
Total Current Assets
Intangible Assets
Short Term Investments
Short Long Term Debt Total
Net Receivables
Short Term Debt
Non Current Liabilities Total
Inventory
Common Stock
Short Long Term Debt
Net Tangible Assets
Current Deferred Revenue
Other Liab
Long Term Debt
Net Invested Capital
Net Working Capital
Capital Stock
Depreciation And Amortization
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Selling And Marketing Expenses
Interest Expense
Research Development
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Net Interest Income
Interest Income
Probability Of Bankruptcy
At this time, Arch Biopartners' Net Debt is fairly stable compared to the past year. Short and Long Term Debt Total is likely to climb to about 6.1 M in 2024, whereas Debt To Equity is likely to drop (0.97) in 2024. At this time, Arch Biopartners' Capex To Depreciation is fairly stable compared to the past year. Days Of Inventory On Hand is likely to climb to 29.63 in 2024, whereas PTB Ratio is likely to drop (19.97) in 2024.
At this time, it appears that Arch Biopartners' Piotroski F Score is Inapplicable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Arch Biopartners is to make sure Arch is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Arch Biopartners' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Arch Biopartners' financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Arch Biopartners' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Arch Biopartners in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.0125)
At this time, Arch Biopartners' Book Value Per Share is fairly stable compared to the past year.
Arch Biopartners Current Valuation Drivers
We derive many important indicators used in calculating different scores of Arch Biopartners from analyzing Arch Biopartners' financial statements. These drivers represent accounts that assess Arch Biopartners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Arch Biopartners' important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Arch Biopartners's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arch Biopartners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arch Biopartners based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.